Today's Top Performers In Drugs

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 30 points (0.2%) at 15,994 as of Thursday, Feb. 13, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,823 issues advancing vs. 1,044 declining with 196 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Pacira Pharmaceuticals ( PCRX), up 11.3%, Celgene Corporation ( CELG), up 2.0%, AstraZeneca ( AZN), up 1.6%, Biogen Idec ( BIIB), up 0.8% and Allergan ( AGN), up 0.8%. A company within the industry that fell today was Regeneron Pharmaceuticals ( REGN), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Valeant Pharmaceuticals International is up $0.80 (0.6%) to $141.57 on average volume. Thus far, 573,541 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $140.00-$141.74 after having opened the day at $140.53 as compared to the previous trading day's close of $140.77.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $47.1 billion and is part of the health care sector. Shares are up 19.9% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Illumina ( ILMN) is up $1.53 (1.0%) to $160.47 on average volume. Thus far, 837,754 shares of Illumina exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $159.48-$161.10 after having opened the day at $160.20 as compared to the previous trading day's close of $158.94.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $20.4 billion and is part of the health care sector. Shares are up 43.7% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts who rate Illumina a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Illumina Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Amgen ( AMGN) is up $1.08 (0.9%) to $123.29 on light volume. Thus far, 647,033 shares of Amgen exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $121.22-$123.50 after having opened the day at $121.65 as compared to the previous trading day's close of $122.21.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $91.4 billion and is part of the health care sector. Shares are up 7.1% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

Automakers Slump as Trump Launches National Security Probe into US Car Imports

Automakers Slump as Trump Launches National Security Probe into US Car Imports

Deutsche Bank Confirms Massive Job Cuts as New CEO Christian Sewing Plants Flag

Deutsche Bank Confirms Massive Job Cuts as New CEO Christian Sewing Plants Flag

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market